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Atherosclerotic peripheral arterial occlusive disease represents
a significant burden; both to patients who carry the diagnosis and
to the healthcare system. Claudication is simply one manifestation
of a systemic process, and recognition of this fact has fueled
comparative studies such as the Claudication: Exercise Versus
Endoluminal Revascularization (CLEVER) trial, described by
Murphy and colleagues, and updated in this issue of the Journal.1
Any contemporary comparative effectiveness trial examining clau-
dication should therefore focus not only on traditional measures of
claudication, but on the systemic effects of atherosclerosis, and the
economic sustainability of any proposed treatment strategy.
The rationale for the study is that anatomic-based treatment
alone does not offer the same potential benefits afforded to sys-
temic therapy, namely exercise therapy and medical optimization.
High-profile trials have demonstrated the equivalence of systemic
treatment to revascularization in the coronary vascular bed inmany
patient populations.2 The non-interventional cohorts in the
CLEVER study have the additive benefits of exercise therapy
(supervised and non-supervised) and represent appropriately
managed patients by contemporary standards. There are several
obvious critiques to the trial setup, including anatomic restric-
tion to the aortoiliac segment, lack of medical management
followed by conditional interventional therapy (patients who
fail conservative measures), and small sample size with restricted
follow-up, which will limit the ability to observe the potential
long-term benefits of sustained exercise therapy. Still, the col-
laborators are to be commended for executing a controlled
claudication trial designed to address the systemic management
of atherosclerosis.
The importance of randomized trials such as the CLEVER
study in vascular disease management cannot be overstated. Endo-
vascular treatments have undoubtedly lowered the morbidity of
revascularization procedures, and benefited enumerable patients.
However, the widespread adoption of endovascular therapy for the
stable disease process of claudication has largely been advanced
without rigorous trials and in many cases without proper attention
to the medical management of the systemic disease process. How-
ever, with a renewed interest in cost effective healthcare, there is an
avenue to reverse this trend.Comparative effectiveness research has been embraced by the
federal government, and in fact, funding has been set aside in the
America Recovery and Reinvestment Act. In this setting, multi-
center comparative trials such as this are essential to the process of
data-driven healthcare reform. Equipped with randomized trial
data, vascular providers will be able guide individual patient treat-
ment, freed from anecdotal reports and marketing-driven presen-
tations that support an array of untested procedures.
Furthermore, payors should have a keen interest in the cost-
efficacy outcomes from this trial. Should supervised exercise ther-
apy and medical optimization prove to be effective, there is a
potential to change the landscape so that these services, which are
not currently covered, become reimbursed. What more could
vascular providers, patients, and society want other than to reim-
burse a therapy that treats the systemic risk factors for atheroscle-
rosis and improves overall patient health?
Many critics of comparative effectiveness based care worry that
its application will threaten the personal nature of the doctor-
patient relationship.3 There is this potential, but vascular surgeons,
who are the only comprehensive providers of vascular care, should
welcome the opportunity to have real scientific data upon which to
recommend care to their patients, whether it be by medical,
interventional, or surgical means. The challenge to our specialty
will be to assume a prominent leadership role in trial design,
conduct, and real-world implementation, so as to provide individ-
ualized, financially responsible, and scientifically-driven care.
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